Experts estimate more than 6 million Americans are living with Alzheimer’s dementia. But a recent study, led by the University of Cincinnati, sheds new light on the disease and a highly debated new drug therapy.
The UC-led study, conducted in collaboration with the Karolinska Institute in Sweden, claims that the treatment of Alzheimer’s disease might lie in normalizing the levels of a specific brain protein called amyloid-beta peptide. This protein is needed in its original, soluble form to keep the brain healthy, but sometimes it hardens into “brain stones” or clumps, called amyloid plaques.
The study, which appears in the…
